Chemomab Therapeutics Ltd. reported topline results from secondary analyses of its Phase 2a liver fibrosis trial assessing CM-101, its first- in-class CCL24-neutralizing antibody, in patients with non-alcoholic steatohepatitis (NASH). The results were included in a late-breaking poster presentation at the 2023 EASL Congress in Vienna, Austria. Overall, the data showed improvements across an additional set of inflammatory and fibrotic biomarkers that are consistent with the positive clinical results Chemomab released in January.

Additionally, in NASH patients at greater risk of disease progression, CM-101 treatment resulted in a greater biomarker response than in NASH patients with lower risk disease or in placebo-treated patients. The new analyses assessed additional biomarkers and also used the FibroScan-AST (FAST) score to categorize study patients based on progressive disease risk, thereby enabling the evaluation of CM-101 activity in the main target population of patients with more active disease.(2) FAST is a validated score composed of non-invasive FibroScan(R) and AST measurements that is used to identify patients with a high risk of NASH progression. The results showed that: FT scorores were improved in a higher proportion of CM-101-treated patients than in placeboatients.

CM-101-treated patients with higher FAST scores demonstrated greater improvements in key fibro-inflammatory biomarkers, such as Pro-C3, than patients with lower FAST scores or placebo patients. CM-101- treated patients with higher FAST scores showed improvements in several recent successful NASH clinical trials. In these secondary analyses, CM-101-treated patients showed improvements in an additional set of biomarkers associated with active fibrosis and inflammation: FIB-4, anan index for determining NASH status that includes age, platelet count, AST and ALT levels, w was improved in CM-101-treated patients vs.

placebo patients. AST/ALT ratio, a liver enzyme ratio, was improved in CM-101 treated patients vs. placebo patients.

Neutrophil-to-Lymphocyte Ratio (NLR), an indicator of inflammation, was improved in CM-101-treated patients vs. placebo patients, and NLR was further improved in groups with higher FAST scores. PRO-C3, which captures active fibrogenesis and correlates with fibrotic disease severity, was improved in CM-101-treated patients vs.

placebo patients and was further improved in groups with higher FAST scores. As an overall indicator of fibrogenesis and fibrotic disease, PRO-C3 is also considered a "bridge" to PSC and other anti-fibrotic indications.